Only Dymista offers fast relief✱ and inflammation control—with every dose1,2
First timepoint (30 minutes) at which Dymista significantly improved, and continued to improve, seasonal nasal allergy symptoms vs placebo in patients age 12 years and older.1
Dymista provided a significant improvement in TNSS compared with both azelastine HCI and fluticasone propionate comparators. The azelastine HCl and fluticasone propionate comparators used the same device and vehicle as Dymista and are not commercially marketed.1,3
References: 1. Dymista [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc., a Mylan Company; 2018. 2. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10. 3. Data on file. Meda Pharmaceuticals Inc., a Mylan Company; 2015.